晚期非小细胞肺癌的治疗进展（Advances in the treatment of advanced non-small cell lung cancer）.docVIP

下载本文档

7
0
约1.59万字
约 9页
2017-07-24 发布于河南
举报
版权申诉

晚期非小细胞肺癌的治疗进展（Advances in the treatment of advanced non-small cell lung cancer）.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

晚期非小细胞肺癌的治疗进展（Advances in the treatment of advanced non-small cell lung cancer）

晚期非小细胞肺癌的治疗进展（Advances in the treatment of advanced non-small cell lung cancer） In recent years, the incidence and mortality of lung cancer in the world have risen significantly, among which 75%, 80% are non-small cell lung cancer (NSCLC). The application of multidisciplinary therapies and molecular targeted drugs has become the focus of late NSCLC research. With the rapid development of molecular biology and pharmacogenomics, individualized treatment of lung cancer has been gradually applied in clinical practice. At present, the treatment of advanced NSCLC has made great progress, and survival has been improved obviously. Lung cancer is becoming a chronic stage, and the application of chemotherapy combined with molecular targeted drugs has become the research focus of breakthrough platform. Angiogenesis inhibitor bevacizumab (Avastin) is the first target drug that has been shown to have a survival advantage in combination with chemotherapy. ECOG in combination with paclitaxel / carboplatin treatment compared with paclitaxel / carboplatin chemotherapy in advanced non squamous NSCLC, not only significantly improve the objective response rate and progression free survival, but also significantly prolong the survival time of the patients. Another study of first-line chemotherapy combined with bevacizumab in the treatment of advanced NSCLC multicenter phase III clinical trial (AVAIL), showed that bevacizumab could significantly prolong progression free survival, treatment response rate and remission duration also increased. Recombinant human endostatin (Endostar, YH 16) phase III study results showed that Endostar combined with NP regimen combined to give patients a survival benefit, R Wu analysis in patients with the median survival time was 385 days, the control group for 278 days, showed better survival advantage. In 2008 the American Society of Clinical Oncology (ASCO) annual meeting, FLEX clinical study of a multicenter randomized controlled phase II I: compared wi